These findings are the first to demonstrate that in SSc patients with genomic evidence of enhanced JAK/STAT pathway activity in target organs, TOF treatment might be effective in slowing or reversing fibrosis [9]. This evidence concerns the gene SOAT1 and systemic sclerosis.